Denosumab-Bmwo
Brand Names: Stoboclo, Osenvelt
Methodology & AI Transparency ⓘ
Denosumab-Bmwo Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Stoboclo is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women.
- 2 Real-world patient consensus: 91% patient "Worth It" rating across 6 anonymous logs for Denosumab-Bmwo (RxNorm 2717855).
- 3 Typical cash cost range: Public pharmacy ledger: $185.00 low cash benchmark vs. $453.25 chain retail average ($1578.0628/unit CMS NADAC).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Denosumab-Bmwo include nausea (9.3%), headache (7.5%), dizziness (5.3%).
Ask our AI Specialists anything about Denosumab-Bmwo
Denosumab-Bmwo Mechanism, CYP450 Pathways & DailyMed Monograph
Stoboclo is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women.
12.1 Mechanism of Action Denosumab products bind to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. Denosumab products prevent RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone.
With Biphasic clearance with 5–9 hr terminal t½ under Denosumab-Bmwo maintenance residence kinetics and Complete (~100%) parenteral systemic delivery for Denosumab-Bmwo (120 mg/1.7mL Injection) bioavailability, Denosumab-Bmwo undergoes hepatic enzymatic processing and renal clearance proportional to creatinine clearance (denosumab-bmwo) and establishes therapeutic activity over rapid intravascular/parenteral onset within 15–45 minutes after denosumab-bmwo administration.
Standard adult regimens span 120 mg/1.7mL Injection, 60 mg/mL Injection. Prescribers screen specifically against stoboclo is contraindicated in: patients with hypocalcemia: pre-existing hypocalcemia must be corrected prior to initiating therapy with stoboclo .; pregnant women: denosumab products may cause fetal harm when administered to a pregnant woman., while community micro-logs most frequently note nausea (9.3% of reports), headache (7.5% of reports), dizziness (5.3% of reports).
Avoid overlapping rank ligand inhibitor prescriptions alongside Denosumab-Bmwo to prevent cumulative receptor toxicity.
Botanical enzyme modulators may alter oral first-pass exposure of Denosumab-Bmwo; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Stoboclo is contraindicated in: Patients with hypocalcemia: Pre-existing hypocalcemia must be corrected prior to initiating therapy with Stoboclo .
- Pregnant women: Denosumab products may cause fetal harm when administered to a pregnant woman.
Logged Side-Effect Incidence (6 Reports)
Denosumab-Bmwo Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Denosumab-Bmwo)
Human clinical trial evidence for Denosumab-Bmwo is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Denosumab-Bmwo Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1578.0628/unit (~$47341.88/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 6 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Denosumab-Bmwo Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Denosumab-Bmwo RxNorm Concept ID | 2717855 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1578.0628 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 91.00% Worth It (6 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Denosumab-Bmwo Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Denosumab-Bmwo: FDA labeling (2026-02-05, NDC 72606-037), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Denosumab-Bmwo community threads and patient logs by age, biological sex, dosage, and treatment duration.